• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: High-dose methylprednisolone vs. dexamethasone for COVID-19 pneumonia

byConstance Wu
June 10, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Hospitalized COVID-19 patients receiving high-dose methylprednisolone followed by oral prednisone had improved clinical outcomes compared to patients receiving dexamethasone.

Evidence Rating Level: 2 (Good)

In June 2020, a preliminary report of a study was published comparing hospitalized COVID-19 patients receiving dexamethasone (DXM) 6 mg daily (for 10 days) to patients who didn’t receive corticosteroids. The study found an 11% decrease in mortality for mechanically ventilated patients, and a 2.8% decrease in global mortality. However, it is unknown whether this effect is specific to dexamethasone, or if other corticosteroids would be effective. The current ambispective cohort study compared outcomes of patients on high-dose methylprednisolone (MTP) with those on DXM. This study was conducted at a centre in Colombia, where up until September 14, 2020, the protocol was to treat patients with DXM 6 mg daily for a maximum of 10 days (or until discharge). From September 15 onwards, the protocol changed to MTP 250-500 mg daily for 3 days, then oral prednisone 50 mg daily for 14 days. The cohort consisted of 216 patients, 111 of whom received DXM, and 105 receiving MTP. The results showed that 26.1% of patients in the DXM group developed severe acute respiratory distress syndrome (ARDS), compared to 17.1% in the MTP group. As well, there were lower rates of transfer to the ICU and mortality in the MTP group (4.8% versus 14.4% and 9.5% versus 17.1% respectively). Finally, clinical markers of COVID-19 severity were significantly lower in MTP patients, such as C-reactive protein (2.85, [95% CI 2.3-3.8] versus 7.2 [5.4-9.8], p < 0.0001), and D-dimer (691 [612-874] versus 1083 [740-1565], p = 0.04). Overall, the study found that patients receiving the high-dose methylprednisolone and prednisone treatments had better clinical outcomes than those receiving dexamethasone. However, randomized controlled trials would be needed to provide more robust evidence for this finding.

Click to read the study in PLOSONE

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Worsening kidney function observed following SARS-CoV-2 infection in children

The 2 Minute Medicine Podcast Episode 54

The Scan by 2 Minute Medicine®: Measles Outbreak, Tariffs and Healthcare, Pope’s Pneumonia, and Removing Fluoride from Water:

Tags: CoronaviruspneumoniaSARS-CoV-2
Previous Post

Voclosporin shows clinical promise for treatment of active lupus nephritis

Next Post

#VisualAbstract: Plasma Epstein-Barr virus DNA may have prognostic value for patients with nasopharyngeal carcinoma

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Worsening kidney function observed following SARS-CoV-2 infection in children

May 23, 2025
The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 54

March 21, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Measles Outbreak, Tariffs and Healthcare, Pope’s Pneumonia, and Removing Fluoride from Water:

March 18, 2025
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Hematology

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

February 10, 2025
Next Post
#VisualAbstract: Plasma Epstein-Barr virus DNA may have prognostic value for patients with nasopharyngeal carcinoma

#VisualAbstract: Plasma Epstein-Barr virus DNA may have prognostic value for patients with nasopharyngeal carcinoma

#VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy

#VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy

Ziltivekimab antagonism of IL-6 reduces inflammation and thrombosis in patients with atherosclerotic risk factors

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.